Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the ApcMin/+ mouse model

Carcinogenesis

Volumn 37, Issue 5, 2016, Pages 491-499

  Savari, Sayeh ^a   Chandrashekar, Naveen Kumar ^a   Osman, Janina ^a   Douglas, Desiree ^a   Bellamkonda, Kishan ^a   Jönsson, Gunilla ^a   Juhas, Maria ^a   Greicius, Gedas ^b,c   Pettersson, Sven ^b,c   Sjölander, Anita ^a  

^a LUND UNIVERSITY   (Sweden)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD3 ANTIGEN; CD8 ANTIGEN; CYSTEINYL LEUKOTRIENE 1 RECEPTOR; LEUKOTRIENE RECEPTOR; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; ADENOMATOUS POLYPOSIS COLI PROTEIN, MOUSE; APC PROTEIN; CD45 ANTIGEN; CTNNB1 PROTEIN, MOUSE; CYCLOOXYGENASE 2; LEUKOTRIENE D4 RECEPTOR; MUC2 PROTEIN, MOUSE; MUCIN 2; PTGS2 PROTEIN, MOUSE; PTPRC PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER INFILTRATION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; FAMILIAL COLON POLYPOSIS; FEMALE; GENDER; INCIDENCE; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMALL INTESTINE MUCOSA; SMALL INTESTINE TUMOR; ANIMAL; BLOOD; C57BL MOUSE; COLORECTAL TUMOR; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; INTESTINAL POLYPS; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; SMALL INTESTINE; TUMOR ASSOCIATED LEUKOCYTE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTIGENS, CD45; BETA CATENIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTESTINAL POLYPS; INTESTINE, SMALL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUCIN-2; NEOPLASMS, EXPERIMENTAL; RECEPTORS, LEUKOTRIENE;

EID: 84964884533     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw031     Document Type: Article

References (54)

1. Ferlay, J., et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127, 2893-2917.
2. Huxley, R.R., et al. (2009) The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int. J. Cancer, 125, 171-180.
3. Guagnozzi, D., et al. (2012) Colorectal cancer surveillance in patients with inflammatory bowel disease: what is new? World J. Gastrointest. Endosc., 4, 108-116.
4. Savari, S., et al. (2014) Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World J. Gastroenterol., 20, 968-977.
5. Chan, C.C., et al. (1990) Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur. J. Pharmacol., 191, 273-280.
6. Barnes, N.C., et al. (1984) Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax, 39, 500-504.
7. Drazen, J.M., et al. (1980) Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl Acad. Sci. USA, 77, 4354-4358.
8. Marom, Z., et al. (1982) Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am. Rev. Respir. Dis., 126, 449-451.
9. Samuelsson, B. (2000) The discovery of the leukotrienes. Am. J. Respir. Crit. Care Med., 161(2 Pt 2), S2-S6.
10. Brink, C., et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev., 55, 195-227.
11. Magnusson, C., et al. (2010) Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur. J. Cancer, 46, 826-835.
12. Matsuyama, M., et al. (2007) Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol. Rep., 18, 99-104.
13. Matsuyama, M., et al. (2009) Relationship between cysteinyl-leukotriene-1 receptor and human transitional cell carcinoma in bladder. Urology, 73, 916-921.
14. Sveinbjörnsson, B., et al. (2008) Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J., 22, 3525-3536.
15. Zhang, W.P., et al. (2004) Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci. Lett., 363, 247-251.
16. Magnusson, C., et al. (2011) Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. Int. J. Cancer, 129, 9-22.
17. Kondeti, V., et al. (2016) Leukotriene D4 and prostaglandin E2 signals synergize and potentiate vascular inflammation in a mast cell-dependent manner through cysteinyl leukotriene receptor 1 and E-prostanoid receptor 3. J. Allergy Clin. Immunol., 137, 289-298.
18. Salim, T., et al. (2014) The inflammatory mediator leukotriene D(4) induces subcellular beta-catenin translocation and migration of colon cancer cells. Exp. Cell Res., 321, 255-266.
19. Bellamkonda, K., et al. (2015) The impact of inflammatory lipid mediators on colon cancer-initiating cells. Mol. Carcinog., 54, 1315-1327.
20. Moser, A.R., et al. (1995) ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer, 31A, 1061-1064.
21. Savari, S., et al. (2013) CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One, 8, e73466.
22. Maekawa, A., et al. (2002) Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem., 277, 20820-20824.
23. Yoo, C.B., et al. (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev. Res. (Phila.), 1, 233-240.
24. McAlpine, C.A., et al. (2006) Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer, 119, 2339-2346.
25. Cherukuri, D.P., et al. (2014) Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, Apc(Min/+) mice. Mol. Oncol., 8, 169-177.
26. Jacoby, R.F., et al. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60, 5040-5044.
27. Chulada, P.C., et al. (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res., 60, 4705-4708.
28. Wang, D., et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell, 6, 285-295.
29. Nakanishi, M., et al. (2008) Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res., 68, 3251-3259.
30. Giardiello, F.M., et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
31. Higuchi, T., et al. (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer Res., 9, 4756-4760.
32. Steinbach, G., et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
33. Bertagnolli, M.M., et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med., 355, 873-884.
34. Cianchi, F., et al. (2006) Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther., 5, 2716-2726.
35. Ye, Y.N., et al. (2005) Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis, 26, 827-834.
36. Phelps, R.A., et al. (2009) A two-step model for colon adenoma initiation and progression caused by APC loss. Cell, 137, 623-634.
37. Kim, J.I., et al. (2010) Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol. Cancer Res., 8, 569-577.
38. Buchanan, F.G., et al. (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl Acad. Sci. USA, 103, 1492-1497.
39. Terada, N., et al. (2010) Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res., 70, 1606-1615.
40. Kundu, N., et al. (2014) Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res. Treat., 143, 19-31.
41. Velcich, A., et al. (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. Science, 295, 1726-1729.
42. Yang, K., et al. (2008) Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res., 68, 7313-7322.
43. Bateman, E.D., et al. (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J., 31, 143-178.
44. Lee, K.S., et al. (2004) Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J. Allergy Clin. Immunol., 114, 1093-1099.
45. Nozaki, M., et al. (2010) Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. Keio J. Med., 59, 10-18.
46. Gooden, M.J., et al. (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer, 105, 93-103.
47. Galon, J., et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960-1964.
48. Kalinski, P. (2012) Regulation of immune responses by prostaglandin E2. J. Immunol., 188, 21-28.
49. Diederichsen, A.C., et al. (2003) Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother., 52, 423-428.
50. Naito, Y., et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res., 58, 3491-3494.
51. Ling, K.L., et al. (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun., 7, 7.
52. Sellitto, A., et al. (2011) Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J. Clin. Immunol., 31, 1095-1104.
53. Sinicrope, F.A., et al. (2009) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology, 137, 1270-1279.
54. Schabowsky, R.H., et al. (2007) Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs, 8, 1002-1008.